CDBC/BCAAN Education Bite, Originally emailed May 9, 2025
An April 2025 New York Times article has been making news: Have We Been Thinking About A.D.H.D. All Wrong? This article highlights fluctuations in ADHD symptoms, the continuous (not dichotomous) nature of ADHD, and mixed evidence for the long-term benefit of medication for ADHD. Clinicians may want to review this article since it’s making the rounds and you may get questions about it.
From the article – “The failure to find a clear biomarker doesn’t mean that there is no biological basis for A.D.H.D.; most scientists I spoke to agreed that the condition is produced by some combination of biological and environmental forces, though there is little consensus about the relative importance of each. But it does have certain implications for the field, including for the question of medication. If we’re no longer confident that A.D.H.D. has a purely biological basis, does it make sense that our go-to treatment is still rooted in biology?”
The Testing Psychologist podcast discussed this article and gave some specific suggestions for clinicians. It’s worth a listen. Reading the NYT article brought me to a recent update to the Multimodal Treatment of ADHD (MTA) study which I’ll highlight here.
Characteristics and Predictors of Fluctuating Attention-Deficit/Hyperactivity Disorder in the Multimodal Treatment of ADHD (MTA) Study (Sibley, et al., 2024)
This study provides detailed comparison of the MTA’s fluctuating ADHD subgroup to the stable ADHD and remission subgroups. This study included 83% of the original sample who had at least one follow up over 18 years old. Unfortunately, this is not an open-access article. I’ve highlighted a few key points here:
In this MTA long-term follow-up study, fluctuating ADHD occurred in 63.8% of the sample, characterized by alternating periods of remission and recurrence. “The high prevalence and moderate severity of fluctuating ADHD indicates that it may be the standard clinical course of ADHD—not a rare variant. Stable persistence appears to be a less common variant of ADHD (10.8% of sample) characterized by early and lasting risk for comorbid mood problems, elevated substance use, stable impairments, and low medication utilization relative to severity. The recovery (9.1%) and stable partial remission subgroups (15.6%) may be rare variants marked by milder ADHD and protective factors such as low parental psychopathology or elevated comorbid anxiety”
“Among fluctuators, periods of remission (particularly full remission) were associated with higher environmental demands, particularly at younger ages [young adult]…Though fluctuations in demands and remission appear to coincide (particularly at younger ages), it remains unclear whether remission promotes entry into more demanding environments or greater demands facilitate symptom/impairment management…Clinicians should emphasize that ADHD often fluctuates over time and patient monitoring of symptoms is imperative to trigger as-needed return to care.”
References
Sibley, M. H., Kennedy, T. M., Swanson, J. M., Arnold, L. E., Jensen, P. S., Hechtman, L. T., Molina, B. S. G., Howard, A., Greenhill, L., Chronis-Tuscano, A., Mitchell, J. T., Newcorn, J. H., Rohde, L. A., & Hinshaw, S. P. (2024). Characteristics and predictors of fluctuating attention-Deficit/Hyperactivity disorder in the multimodal treatment of ADHD (MTA) study. The Journal of Clinical Psychiatry, 85(4)https://doi.org/10.4088/JCP.24m15395